胫动脉腔内介入后因复发症状性疾病再干预的结局
本研究回顾性分析2006至2016年因严重肢体缺血行孤立胫动脉腔内介入的患者,54%出现症状性再狭窄或闭塞,513例复发患者中64%行再次胫动脉腔内介入、19%行开放旁路、17%行膝下截肢。在具备良好靶血管、静脉导管和足部流出道的患者中,旁路组5年患者中心结局优于再介入组。
要点
- 胫动脉腔内介入后症状性复发率高(54%出现再狭窄或闭塞)。
- 复发患者中64%行再次腔内介入,19%行旁路,17%行膝下截肢。
- 在靶血管、静脉导管和足部流出道良好者中,旁路5年无截肢生存、免于主要不良肢体事件和临床疗效均优于再次腔内介入。
核心结论
- 胫动脉介入治疗严重缺血与高再干预率相关。
- 在靶血管良好、有静脉导管且足部流出道良好的患者中,旁路似乎比重复胫动脉腔内介入更持久。
研究设计与样本
- 回顾性查询2006至2016年间接受孤立初次下肢胫动脉腔内介入的患者数据库。
- 共1134例患者(56%男性,平均年龄59岁)因严重缺血行初次胫动脉介入,其中54%出现症状性再狭窄和闭塞。
- 513例复发患者中58%表现为静息痛,其余为溃疡。
- 定义三组:再次胫动脉或足部腔内介入(64%)、胫动脉或足部旁路(19%)、同侧膝上或膝下截肢(17%,原文描述为below-knee amputation)。
主要发现
- 旁路组患者中心结局优于再介入组:5年无截肢生存率45%±9% vs 27%±9%(P < .01)。
- 旁路组主要不良肢体事件50%±9% vs 再介入组31%±9%(P < .05),原文未说明该数值为免于事件率还是事件发生率。
- 旁路组临床疗效60%±7% vs 再介入组30%±9%(P < .01),均值±标准误,随访5年。
- 旁路应用于靶血管良好、有静脉导管且足部流出道良好的患者。
关键数值与推荐
- 原文未报告具体推荐标准。
临床怎么用
- 在靶血管良好、有静脉导管且足部流出道良好的复发患者中,旁路似乎比重复胫动脉腔内介入更持久。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tibial interventions for critical limb ischemia are now commonplace. Restenosis and occlusion remain barriers to durability after intervention. The aim of this study was to examine the patient-centered outcomes of open and endovascular reintervention for symptomatic recurrent disease after a primary isolated tibial endovascular intervention. METHODS: A database of patients undergoing isolated primary lower extremity tibial endovascular interventions between 2006 and 2016 was retrospectively queried. Patients with recurrent critical ischemia (Rutherford 4 and 5) were identified. Outcomes in this cohort were analyzed, and three groups were defined: endovascular reintervention (ie, a repeated tibial or pedal endovascular intervention), bypass (bypass to a tibial or pedal vessel), and primary amputation (ie, above- or below-knee amputation) on the ipsilateral leg. Patient-oriented outcomes of clinical efficacy (absence of recurrent signs or symptoms of critical ischemia, maintenance of ambulation, and absence of major amputation), amputation-free survival (survival without major amputation), and freedom from major adverse limb events (above-ankle amputation of the index limb or major reintervention, such as new bypass graft or jump or interposition graft revision) were evaluated after the reintervention. RESULTS: There were 1134 patients (56% male; average age, 59 years) who underwent primary tibial intervention for critical ischemia, and 54% presented with symptomatic restenosis and occlusion. Of the 513 patients with recurrent disease, 58% presented with rest pain and the remainder with ulceration. A repeated tibial endovascular intervention was performed in 64%, open bypass in 19%, and below-knee amputation in 17%. Bypass was employed in patients with a good target vessel, venous conduit, and good pedal runoff. Patient-centered outcomes were better in the bypass group compared with the reintervention group (amputation-free survival, 45% ± 9% vs 27% ± 9% [P < .01]; major adverse limb events, 50% ± 9% vs 31% ± 9% [P < .05]; clinical efficacy, 60% ± 7% vs 30% ± 9% [P < .01], mean ± standard error of the mean at 5 years). CONCLUSIONS: Tibial interventions for critical ischemia are associated with a high rate of reintervention. In patients with good target vessel, venous conduit, and good pedal runoff, bypass appears more durable than repeated tibial endovascular intervention.
引用
- Baer-Bositis HE, Hicks TD, Haidar GM, et al. Outcomes of reintervention for recurrent symptomatic disease after tibial endovascular intervention. J Vasc Surg. 2018. PMID: 29525414. doi:10.1016/j.jvs.2017.11.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。